Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA.

J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. doi: 10.1093/jnci/djn150. Epub 2008 May 27.

2.

[The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].

Guo XQ, Gui YT, Cai ZM.

Yi Chuan. 2011 Feb;33(2):117-22. Review. Chinese.

PMID:
21377967
3.

Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.

Farooqi AA, Hou MF, Chen CC, Wang CL, Chang HW.

Cancer Cell Int. 2014 Apr 17;14:34. doi: 10.1186/1475-2867-14-34. eCollection 2014. Review.

4.

Fusion in the ETS gene family and prostate cancer.

Narod SA, Seth A, Nam R.

Br J Cancer. 2008 Sep 16;99(6):847-51. doi: 10.1038/sj.bjc.6604558. Review.

5.

Emerging biological observations in prostate cancer.

Shah S, Small E.

Expert Rev Anticancer Ther. 2010 Jan;10(1):89-101. doi: 10.1586/era.09.161. Review.

PMID:
20014889
6.

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects.

Omoto Y, Iwase H.

Cancer Sci. 2015 Apr;106(4):337-43. doi: 10.1111/cas.12613. Epub 2015 Mar 9. Review.

7.

Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.

Sanguedolce F, Cormio A, Brunelli M, D'Amuri A, Carrieri G, Bufo P, Cormio L.

Clin Genitourin Cancer. 2016 Apr;14(2):117-21. doi: 10.1016/j.clgc.2015.12.001. Epub 2015 Dec 17. Review.

PMID:
26774207
8.

Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.

Yao Y, Wang H, Li B, Tang Y.

Tumour Biol. 2014 Mar;35(3):2157-66. doi: 10.1007/s13277-013-1286-x. Epub 2013 Oct 20. Review.

PMID:
24142545
9.

Signaling networks in TMPRSS2-ERG positive prostate cancers: Do we need a Pied Piper or sharpshooter to deal with "at large" fused oncoprotein.

Lin X, Qureshi MZ, Romero MA, Yaylim I, Arif S, Ucak I, Fayyaz S, Farooqi AA, Mansoor Q, Ismail M.

Cell Mol Biol (Noisy-le-grand). 2017 Feb 28;63(2):1-8. doi: 10.14715/cmb/2017.63.2.1. Review.

PMID:
28364793
10.

[TMPRSS2-ETS gene fusion in prostate cancer].

Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M.

Urologe A. 2007 Jul;46(7):754-60. Review. German.

PMID:
17458530
11.

Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P.

Endocr Relat Cancer. 2004 Sep;11(3):537-51. Review.

12.

ETS gene fusions in prostate cancer.

Clark JP, Cooper CS.

Nat Rev Urol. 2009 Aug;6(8):429-39. doi: 10.1038/nrurol.2009.127. Review.

PMID:
19657377
13.

[New insights into the role of estogens and their receptors in prostate cancer].

Bonkhoff H, Motherby H, Fixemer T.

Urologe A. 2003 Dec;42(12):1594-601. Review. German.

PMID:
14668987
14.

ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).

Shaikhibrahim Z, Wernert N.

Int J Oncol. 2012 Jun;40(6):1748-54. doi: 10.3892/ijo.2012.1380. Epub 2012 Feb 21. Review.

PMID:
22366814
15.

Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer.

Lau KM, To KF.

Int J Mol Sci. 2016 Aug 31;17(9). pii: E1434. doi: 10.3390/ijms17091434. Review.

16.

Recurrent rearrangements in prostate cancer: causes and therapeutic potential.

White NM, Feng FY, Maher CA.

Curr Drug Targets. 2013 Apr;14(4):450-9. Review.

17.

Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium.

Archer LK, Frame FM, Maitland NJ.

J Steroid Biochem Mol Biol. 2017 Feb;166:68-83. doi: 10.1016/j.jsbmb.2016.05.006. Epub 2016 May 14. Review.

PMID:
27185499
18.

ERG expression in prostate cancer: biological relevance and clinical implication.

Abou-Ouf H, Zhao L, Bismar TA.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1781-93. doi: 10.1007/s00432-015-2096-x. Epub 2015 Dec 28. Review.

PMID:
26711283
19.

[Gender-specific colorectal cancer: epidemiologic difference and role of estrogen].

Kim HM, Kim HS.

Korean J Gastroenterol. 2014 Apr;63(4):201-8. Review. Korean.

20.

Estrogen receptor beta in prostate cancer: friend or foe?

Nelson AW, Tilley WD, Neal DE, Carroll JS.

Endocr Relat Cancer. 2014 Aug;21(4):T219-34. doi: 10.1530/ERC-13-0508. Epub 2014 Jan 8. Review.

Supplemental Content

Support Center